Interferon-alpha, particularly in early-stage PV or ET, has demonstrated the ability to induce hematologic remission, reduce JAK2 V617F allele burden, and possibly alter the natural course of the disease. This evidence concerns the gene JAK2 and essential thrombocythemia.